A new article was published in Diabetes, Obesity and Metabolism

Tatiana Yakovleva, Victor Sokolov, Lulu Chu, Weifeng Tang, Peter J. Greasley, Helena Peilot Sjögren, Susanne Johansson, Kirill Peskov, Gabriel Helmlinger, David W. Boulton, Robert C. Penland. Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. Diabetes Obes Metab. 2019 Aug 18. doi: 10.1111/dom.13858.

 Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a class of oral glucose-lowering compounds used to treat type 2 diabetes mellitus (T2DM). In collaboration with AstraZeneca quantitative drug-disease systems model was developed and used to reveal mechanistic differences in renal glucose reabsorption and urinary glucose excretion (UGE) between healthy and T2DM patients and clearly showed that SGLT2 inhibition significantly increased glucose available to SGLT1 downstream in the tubule.